普鲁卡因胺与苯妥英联合治疗期间出现的粒细胞缺乏症。

Agranulocytosis during combined procainamide and phenytoin therapy.

作者信息

Crook J E, Woosley R L, Leftwich R B, Natelson E A

出版信息

South Med J. 1979 Dec;72(12):1599-601. doi: 10.1097/00007611-197912000-00032.

DOI:10.1097/00007611-197912000-00032

Abstract

We have presented two cases of agranulocytosis occurring in patients receiving a combination antiarrhythmic regimen. As multiple drug therapy for ventricular arrhythmias becomes more commonplace, increased scrutiny should be given to agents chosen, in an effort to prevent any possible adverse interactions. When future cases are encountered, the acetylator pheontype should be determined. This information would aid in assessing the predicative value of the acetylator phenotype in the development of agranulocytosis. Due to the inherent danger, neither patient was rechallenged with procainamide nor phenytoin.

摘要

我们报告了两例接受联合抗心律失常方案治疗的患者发生粒细胞缺乏症的病例。随着用于室性心律失常的多种药物治疗变得越来越普遍，应更加仔细地审查所选用的药物，以防止任何可能的不良相互作用。当遇到未来的病例时，应确定乙酰化酶表型。这些信息将有助于评估乙酰化酶表型在粒细胞缺乏症发生中的预测价值。由于存在内在危险，两名患者均未再次使用普鲁卡因胺或苯妥英钠。